Sitemap
Pages
- About / Contact
- About Hypertension
- About-Old
- Clinical Results
- Clinical Trials
- Contact us
- Corporate Governance
- Doctor Resources
- Find a Study Doctor
- Home
- Home – Revised 2021
- Idea Portal
- Medical Education
- News & Events
- Our Technology
- Patents
- Privacy Statement
- Product Feedback
- RADIANCE II
- Site Map
- Sitemap
- Slide Anything Popup Preview
- Terms and Conditions
- Therapy
Posts
- How ReCor Medical is Taking Action to Confront Racism
- Otsuka Medical Devices REQUIRE Trial Results Presented at Japan Society of Hypertension Annual Meeting
- Otsuka Medical Devices, Otsuka Holdings and ReCor Medical Announce Signing of Merger Agreement
- ReCor Medical adds another $12m for trial of Paradise renal denervation device
- Recor Medical and Otsuka Medical Devices Announce Positive Vote from U.S. Food and Drug Administration (FDA) Advisory Committee Meeting on the Paradise™ Ultrasound Renal Denervation System for the Treatment of Hypertension
- ReCor Medical and Otsuka Medical Devices Announce Primary Endpoint Met in the RADIANCE II US Pivotal Trial of the Paradise™ System for the Treatment of Hypertension
- ReCor Medical and Otsuka Medical Devices Announce Submission of Application for Pre-Market Approval of the Paradise™ Ultrasound Renal Denervation (uRDN) System to the U.S. Food and Drug Administration
- ReCor Medical Announces 1000th Enrollment and 150th Randomization in RADIANCE-HTN Hypertension Study
- ReCor Medical Announces 6 Month On-Medication Results from RADIANCE-HTN SOLO Clinical Trial and the First Randomization in the RADIANCE-II Pivotal Study
- ReCor Medical Announces Collaboration and Investment with Otsuka Holdings for Asian Commercialization and Clinical Studies in the US and Europe
- ReCor Medical Announces Completion of Enrollment in RADIANCE-II Pivotal Trial of the Paradise™ Ultrasound Renal Denervation System for the Treatment of Uncontrolled Hypertension
- ReCor Medical Announces Completion of RADIANCE-HTN SOLO Hypertension Study
- ReCor Medical Announces Consistent Reduction of Blood Pressure in Pooled Analysis of Three Clinical Trials at AHA 2022
- ReCor Medical Announces FDA Approval of IDE for Pivotal Study of Paradise™ Ultrasound Denervation System for Treatment of Hypertension
- ReCor Medical Announces IDE Approval for RADIANCE-HTN Hypertension Clinical Trial
- ReCor Medical Announces Initial Enrollments in the RADIANCE-HTN Hypertension Clinical Trial
- ReCor Medical Announces New Lead Investor and Upcoming Hypertension Trial
- ReCor Medical Announces Positive Results in RADIANCE-HTN TRIO Study and Breakthrough Device Designation for Paradise™ Ultrasound Renal Denervation System
- ReCor Medical Announces RADIANCE-HTN SOLO Hypertension Study Meets Primary Efficacy Endpoint, Pivotal Study Submission, and New Principal Investigator
- ReCor Medical Announces Results from Landmark RADIANCE-HTN TRIO Study, Showing Clinically Significant Blood Pressure Reduction with the Paradise Ultrasound RDN System in Patients with Resistant Hypertension
- ReCor Medical Announces Results of Pooled Data Analysis from RADIANCE SOLO and TRIO Studies in Treating Hypertension with the Paradise Ultrasound Renal Denervation System
- ReCor Medical Announces Results of RADIANCE II Pivotal Trial at TCT 2022 Annual Meeting
- ReCor Medical Announces Two Concurrent JAMA Network Publications of Study Results on the Paradise Ultrasound Renal Denervation System for the Treatment of Hypertension
- ReCor Medical Launches the Paradise™ Ultrasound Renal Denervation for the Treatment of Hypertension in Europe
- ReCor Medical Names Lara Barghout President and Chief Executive Officer
- ReCor Medical reports latest data from landmark renal denervation clinical trials at TCT Annual Meeting
- ReCor Medical To Release Clinical Trial Results May 23 at EuroPCR in Paris
- Recor Medical Unveils Refreshed Brand to Showcase Company’s Vision for the Future
- ReCor Responds to European Society of Hypertension’s (ESH) Updated Guidelines for Management of Arterial Hypertension
- ReCor update on the RADIANCE Clinical Program